GeoVax Labs, Inc., a biotechnology company developing human vaccines and cancer immunotherapies, announced its participation in the upcoming 3rd Annual ROTH Healthcare Opportunities Conference scheduled for October 9, 2024, in New York. The company's Chairman and CEO, David Dodd, will participate in a panel discussion titled "Innovative Therapies for Solid Tumors" at 12:30 pm ET during the conference. This participation emphasizes GeoVax's commitment to advancing its oncology program, particularly its lead clinical program Gedeptin®, which is undergoing a multicenter Phase 1/2 clinical trial for advanced head and neck cancers.
The conference provides a platform for GeoVax to showcase progress in developing novel therapies for solid tumors, an area of oncology presenting significant challenges and opportunities for innovation. It also enables engagement with industry peers, potential investors, and healthcare professionals, potentially fostering new collaborations. The company's participation draws attention to its broader portfolio of clinical programs, including multiple Phase 2 clinical trials for its next-generation COVID-19 vaccine, GEO-CM04S1. These trials evaluate the vaccine's efficacy as a primary vaccine for immunocompromised patients, a booster for patients with chronic lymphocytic leukemia, and a more robust booster for healthy patients who previously received mRNA vaccines.
GeoVax recently received a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial comparing GEO-CM04S1 to an approved COVID-19 vaccine. This large-scale trial represents a significant milestone with potential implications for COVID-19 vaccination strategies, especially for vulnerable populations. The company's diverse pipeline spanning infectious diseases and oncology positions it at the forefront of addressing pressing medical challenges. GeoVax's approach to developing novel vaccines and immunotherapies could offer new treatment options for patients with limited alternatives.
Events like the ROTH Healthcare Opportunities Conference play a crucial role in highlighting innovative companies and technologies as the biotechnology sector evolves rapidly. For GeoVax, this conference represents an opportunity to establish its presence in the competitive landscape of cancer immunotherapies and vaccine development. Investors and industry observers will likely monitor updates emerging from the company's participation, as progress in both COVID-19 vaccine and oncology programs could have significant implications for public health and cancer treatment strategies. For more information about GeoVax's clinical programs and technologies, interested parties can visit the company's website. GeoVax's participation in such events demonstrates its ongoing commitment to innovation in biotechnology and healthcare.
